Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.

Johnson, Aishwarya Mary; Barigye, Robert; Saminathan, Hariharan

Johnson, Aishwarya Mary; Barigye, Robert; Saminathan, Hariharan.

Afiliação

Johnson AM; Department of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab Emirates.
Barigye R; Department of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab Emirates.
Saminathan H; Department of Veterinary Medicine, College of Food and Agriculture, United Arab Emirates University, Abu Dhabi, United Arab Emirates.

Hum Vaccin Immunother ; 17(9): 2824-2840, 2021 09 02.

Article em En | MEDLINE | ID: mdl-33974497

Assuntos

COVID-19; Síndrome da Liberação de Citocina; Anticorpos Monoclonais/efeitos adversos; Citocinas; Humanos; SARS-CoV-2

Palavras-chave

COVID-19; adverse effects; immunotherapeutics; monoclonal antibodies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome da Liberação de Citocina / COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Emirados Árabes Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google